Lexeo Therapeutics, Inc. financial data

Symbol
LXEO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, Floor 6, New York, New York
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity 2.79 K % +4441%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.7 M shares
Common Stock, Shares, Outstanding 32.9 M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 3 K USD
Weighted Average Number of Shares Outstanding, Basic 28 M shares +1637%
Weighted Average Number of Shares Outstanding, Diluted 28 M shares +1637%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.7 M USD -4.23%
General and Administrative Expense 7.55 M USD +165%
Operating Income (Loss) -23.3 M USD -20.7%
Nonoperating Income (Expense) 1.61 M USD +154%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.7 M USD -16.2%
Net Income (Loss) Attributable to Parent -69.4 M USD -6.1%
Earnings Per Share, Basic -0.77 USD/shares +93.4%
Earnings Per Share, Diluted -0.77 USD/shares +93.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 195 M USD
Other Assets, Current 3 K USD -99.2%
Assets, Current 198 M USD
Property, Plant and Equipment, Net 1.04 M USD
Operating Lease, Right-of-Use Asset 9.12 M USD
Assets 213 M USD
Accounts Payable, Current 4.3 M USD
Liabilities, Current 21.6 M USD
Operating Lease, Liability, Noncurrent 7.47 M USD
Liabilities 30.3 M USD
Retained Earnings (Accumulated Deficit) -204 M USD
Stockholders' Equity Attributable to Parent 183 M USD
Liabilities and Equity 213 M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9 M USD +19.1%
Net Cash Provided by (Used in) Financing Activities 88.7 M USD
Net Cash Provided by (Used in) Investing Activities -193 K USD
Common Stock, Shares Authorized 500 M shares
Common Stock, Shares, Issued 32.9 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 73.6 M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 198 M USD +219%
Deferred Tax Assets, Valuation Allowance 62 M USD +63.1%
Deferred Tax Assets, Gross 65.3 M USD +54.7%
Operating Lease, Liability 9.56 M USD
Payments to Acquire Property, Plant, and Equipment 185 K USD
Lessee, Operating Lease, Liability, to be Paid 11.9 M USD
Property, Plant and Equipment, Gross 1.49 M USD
Operating Lease, Liability, Current 2.09 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.21 M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.15 M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.34 M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.26 M USD
Deferred Tax Assets, Operating Loss Carryforwards 21.9 M USD +42.4%
Preferred Stock, Shares Authorized 10 M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.32 M USD
Operating Lease, Payments 530 K USD -3.29%
Deferred Tax Assets, Net of Valuation Allowance 3.37 M USD -20.5%
Share-based Payment Arrangement, Expense 2.33 M USD +487%
Interest Expense 37 K USD -26%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares